FDA Officials Highlight Compliance and Warning Letter Trends

International Pharmaceutical Regulatory Monitor
A A
CDER’s Office of Manufacturing Quality issued 45 warning letters through Sept. 1 of this year, not counting actions against compounders, according to Francis Godwin, a division director in OMQ.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor